SeekInClarity Offers Promise in Monitoring Cancer Treatment Response
A new prospective study in BMC Cancer shows that the blood-based multi-omics test SeekInClarity accurately predicts treatment outcomes.
A new prospective study in BMC Cancer shows that the blood-based multi-omics test SeekInClarity accurately predicts treatment outcomes.
Echosens and Boehringer Ingelheim have expanded their partnership to improve early detection, diagnosis, and care access for MASH.
Personalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Researchers developed an AI-driven blood test, ARTEMIS-DELFI, that detects pancreatic cancer treatment response faster and more accurately.
Read MoreThe FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read MoreA groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read MoreOncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough.
Read MoreTeal Health has received FDA approval for the Teal Wand, a prescription-based self-collection device for cervical cancer screening.
Read MoreNew predictive algorithms using routine health data and blood tests significantly improve early detection of 15 cancers.
Read MoreA new peer-reviewed study confirms that Ibex Breast significantly enhances accuracy, speed, and efficiency of breast pathology evaluations.
Read MoreRoche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Read MoreFellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.
Read MoreMursla Bio has received FDA Breakthrough Device Designation for EvoLiver, a novel blood test using Dynamic Biopsy technology.
Read MoreVeracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
Read MoreA new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
Read MoreBiodesix and Bio-Rad contributed findings to ctMoniTR showing that changes in ctDNA are strongly associated with treatment outcomes.
Read MoreLabcorp has expanded its precision oncology portfolio with two diagnostic tools—Labcorp Plasma Detect and PGDx elio plasma focus Dx.
Read MoreLiquid biopsy is a groundbreaking, non-invasive method for early cancer detection and monitoring, offering significant clinical potential.
Read More